Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL ...

Patients with oligometastatic lung cancer may live longer with surgery, but experts stress the need for multidisciplinary ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

Novocure's PANOVA-3 trial shows that the TTFields combo boosts survival in pancreatic cancer, hitting the primary endpoint.

Primary surgery for advanced ovarian cancer significantly improves progression-free survival but not overall survival ...

A long-term follow-up of early total therapy trials suggests that up to one-third of patients with newly diagnosed multiple ...

TP53 aberrations and circulating tumor DNA burden were found to be predictors of poor outcomes in high-risk patients with ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", 6990.HK) today announced that results from its ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Analysts at Truist Securities called the mid-stage data a "mixed bag," also flagging gastrointestinal adverse events. However ...

A new FDA application for vepdegestrant offers hope for advanced breast cancer patients with ESR1 mutations, showcasing ...

EU approves AstraZeneca’s Calquence in combo with venetoclax, with or without obinutuzumab to treat adult patients with previously untreated CLL: Cambridge, UK Saturday, June 7, ...